Disc Medicine, Inc.

Equities

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
27.55 ^USD	+3.88%		-3.97%	-52.30%

Apr. 08	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT
Apr. 02	Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	MT

Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 21, 2024 at 08:16 am EDT

Disc Medicine, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 76.43 million compared to USD 46.83 million a year ago. Basic loss per share from continuing operations was USD 3.42 compared to USD 45.05 a year ago.

Latest news about Disc Medicine, Inc.

Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	Apr. 08	MT
Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	Apr. 02	MT
Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating	Apr. 02	MT
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating	Apr. 02	MT
Stifel Adjusts Price Target on Disc Medicine to $71 From $104, Keeps Buy Rating	Apr. 02	MT
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept	Apr. 02	MT
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Top Midday Decliners	Apr. 01	MT
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	Apr. 01	MT
Raymond James Downgrades Disc Medicine to Outperform From Strong Buy, Cuts Price Target to $40 From $75	Apr. 01	MT
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	Apr. 01	CI
Wedbush Raises Disc Medicine Price Target to $84 From $79, Maintains Outperform Rating	Mar. 21	MT
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Stifel Adjusts Price Target on Disc Medicine to $104 From $76, Maintains Buy Rating	Mar. 12	MT
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer	Feb. 26	MT
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer	Feb. 26	CI
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	Feb. 20	MT
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	Feb. 20	CI
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation	Feb. 09	MT
Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment	Feb. 09	DJ
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	Feb. 09	CI
Disc Medicine, Inc. Announces Promotion of Jonathan Yu to Chief Operating Officer	Feb. 07	CI
Disc Medicine, Inc. Announces CFO Changes	Feb. 07	CI
Disc Medicine Insider Sold Shares Worth $6,934,125, According to a Recent SEC Filing	Jan. 25	MT
Disc Medicine Insider Sold Shares Worth $1,280,000, According to a Recent SEC Filing	Jan. 12	MT

Chart Disc Medicine, Inc.

Duration

Period

More charts

Company Profile

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.55 USD

Average target price

57.11 USD

Spread / Average Target

+107.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DISC MEDICINE, INC.	-52.30%	680M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research